| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Emergency Medicine, Oncology |
| Credits Available: | 4.25 AMA PRA Category 1 Credit™; ABIM MOC |
Rigorous clinical research has led to the discovery of novel immunologic therapies. Chimeric antigen receptor T cell (CAR T-cell) therapy has shown impressive outcomes but is associated with a significant risk of adverse events (AEs), chiefly cytokine release syndrome (CRS). Bispecific antibodies act through a similar mechanism of action but offer a lower risk of CRS. These AEs may require immediate management, which may occur in the emergency department (ED) setting.
Given the novelty and specialty nature of bispecific antibody and CAR T-cell therapies, ED clinicians face several challenges in the practical management of patients receiving these therapies. Similarly, given the breadth of conditions treated with these therapies, ED clinicians may face difficulties knowing which patient populations are at risk. While CAR T therapies are approved for hematologic malignancies, bispecific antibodies are approved for many indications including hematologic malignancies, non-small cell lung cancer, uveal melanoma, hemophilia A, and neovascular macular edema. This collaborative social learning platform establishes a network of providers who can create a sustainable network of providers who can continue to support each other following this experience in implementing their practice action plans aimed at improving the care provided to patients on CAR T or bispecific therapies.
The following questions are designed to assess your knowledge and practice of patients with cytokine release syndrome.
In this module, we’ll build a foundation of knowledge about bispecific antibodies and CAR T-cell therapies—their indications, mechanisms, and typical adverse events.
In this module we’ll delve deeper into how to identify CRS: understanding risk factors, working up patients, and applying grading scales.
In this module we will explore management principles, including when to use specific therapies and when to involve oncologists and ICU teams.
The following questions are designed to assess your gained knowledge and practice of patients with cytokine release syndrome.
68 yo male with presents to ER with fever, SOB, and hypotension, after treatment with CAR-T. Requires further workup. Later, new neurologic changes.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with CRS.
During this session, we will review the self-study modules, review the patient case and discuss treatment plans. We will hear from a guest speaker, share our action plans, and discuss how this CME activity will shape our practice regarding patient care.
